Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker
Novartis stock slumped Tuesday — undercutting the lower boundary of a flat base — after sales of its biggest moneymaker expectations. Continue reading View comments
There is no Profile data available for NOT.SG.
75.1111 | |
75.1111 | |
- | |
75.1111 | |
75.1111 | |
71.8111-75.1111 | |
160 075 M | |
0 | |
0 | |
0.0356 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Novartis stock slumped Tuesday — undercutting the lower boundary of a flat base — after sales of its biggest moneymaker expectations. Continue reading View comments
The pharmaceutical giant raised its full-year guidance for the third time this year after higher third-quarter profit and sales topped analysts’ expectations, boosted by revenue from its key drugs. Continue reading View comments
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: